Applied Therapeutics, Inc. (NASDAQ:APLT – Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 19,160,000 shares, a growth of 5.6% from the December 15th total of 18,150,000 shares. Based on an average daily trading volume, of 5,880,000 shares, the short-interest ratio is presently 3.3 days.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. SG Americas Securities LLC lifted its position in Applied Therapeutics by 169.0% in the fourth quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after acquiring an additional 25,601 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Applied Therapeutics by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company’s stock valued at $268,000 after purchasing an additional 47,983 shares during the last quarter. Barclays PLC lifted its holdings in shares of Applied Therapeutics by 186.1% in the 3rd quarter. Barclays PLC now owns 200,012 shares of the company’s stock valued at $1,702,000 after purchasing an additional 130,102 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Applied Therapeutics in the 3rd quarter valued at about $149,000. Finally, XTX Topco Ltd purchased a new position in Applied Therapeutics during the 3rd quarter worth approximately $531,000. Institutional investors and hedge funds own 98.31% of the company’s stock.
Wall Street Analyst Weigh In
APLT has been the topic of several analyst reports. Royal Bank of Canada reduced their price objective on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating on the stock in a research note on Friday, December 20th. Citigroup decreased their price objective on Applied Therapeutics from $13.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 29th. William Blair lowered shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. UBS Group reiterated a “neutral” rating and issued a $2.00 price target (down previously from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. Finally, Robert W. Baird dropped their price objective on shares of Applied Therapeutics from $14.00 to $5.00 and set an “outperform” rating on the stock in a research report on Friday, November 29th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $6.10.
Applied Therapeutics Stock Up 5.3 %
Shares of APLT opened at $0.65 on Tuesday. The company has a market capitalization of $75.98 million, a price-to-earnings ratio of -0.41 and a beta of 1.83. Applied Therapeutics has a 52-week low of $0.60 and a 52-week high of $10.62. The stock has a 50 day moving average price of $3.13 and a 200 day moving average price of $5.57.
About Applied Therapeutics
Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
See Also
- Five stocks we like better than Applied Therapeutics
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- 5 discounted opportunities for dividend growth investors
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.